19.3 (13.9) #{149} Activitymeasuredin untreated samples relativeto the activity measured in gel-filtered samples. b P <0.001, signiflcantiy different(pairedt4est)fromactivity measuredinuntreated urine samples. C P <0.01 and d P <0.001, significantly different (ttest) fromrelativeactivityobtained for healthy adults. Relativeactivity %, mean (and SD) 68. 9 (20.8) L-Alanine-4-nitroanilide is the most widely acceptedand most convenient substrate for determination of this enzyme (2). Meanwhile, three well-documented methods have been described in which this substrate was used (2-4). These methods differ in reaction temperature, buffer, buffer and substrate concentration, and especially in the sample, either native or gel-filtered urine. Whereas Mattenheimer et al.
How Should We Measure Activity of Aianlne Aminopeptidase In Urine?
To the Editor:
Alanine aminopeptidase [AAP; aaminoacyl-peptide hydrolase (microsomal), EC 3.4.11.2] has proved to be a suitable urinary enzyme to use in detecting renal disorders (1), and numerous tests for determination of its activity have been recommended (2).
L-Alanine-4-nitroanilide is the most widely acceptedand most convenient substrate for determination of this enzyme (2) . Meanwhile, three well-documented methods have been described in which this substrate was used (2) (3) (4) . These methods differ in reaction temperature, buffer, buffer and substrate concentration, and especially in the sample, either native or gel-filtered urine. Whereas Mattenheimer et al. (2) and we (3) considered it necessary to remove enzyme inhibitors from urine by gel-filtration, Flandrois et al. We set the activity values measured in samples after gel ifitration at 100% and calculated the percentages of the activities in untreated urine samples ( Table 1) . Except for Method ifi in renal-transplant recipients, the gelifitered samples showed higher AA1' activities than untreated samples. The activities in untreated urine samples compared with activities measured in gel-ifitered samples, indicated in Table 1 as relative activities, were significantly lower in healthy persons than in renal-transplant recipients. We conclude that concentrations of enzyme inhibitors are higher in urine samples of healthy persons than in those of renal-transplant recipients, and that their inhibitory effects are diminished by increasing substrate concentration.
However, the recommended substrate concentration of 
Estimation of Sensitivity of lmmunoassays
McConway et al.
(1) advocate use of the precision profile to determine the minimum detection limit (MDL) of immunoassays, arguing that the MDL (with 95% confidence) is the concentration corresponding to a CV of 22% read from the precision profile. They are correct in emphasizing the scatter of sample, rather than the zero-standard estimates in estimating the MDL, but readers should note that their argument is based on the incorrect use of statistics and that it makes some assumptions about immunoassays that are unlikely to be met in practice.
With regard to the statistics set out in the appendix to their paper, the errors in their argument are as follows:
1) "The standard error" (SE) referred to in the denominator of their equation 1 is unspecified, but would, in computing the t statistic as shown, be the SE of the difference in the means (X1 -X2). This should be calculated as the square root of the sum of the variances of X1 and X2, and not, as shown, as the SE of X1. Their calculation incorrectly assumes that the estimate of the mean response at zeroanalyte concentration is error-free, and will, therefore, underestimate the MDL.
2) The statistics X1, X2, and SD are in units of the response variable up to equation 2, but subsequently they are interpreted as being in concentration units. The nonlinear relationship between response variable and concentration implies that measures of scatter for these quantities are not easily transposed. It is misleading of the authors to introduce this transposition without making it explicit, and without demonstrating that it is valid to do so.
3) In calculating, albeit incorrectly, the CV at the MDL as being 22%, readers will note that this CV describes the scatter when test results are derived from single measurements. As the study described by the authors used duplicate measurements for each test result, the CVs reported in the precision proffles would apply to the scatter based on the mean of duplicate measurements. These two measures of scatter are not directly comparable, the latter being lower by a factor of \/.
In addition to these errors of commission, the authors omit to make clear the limitations of using the precision proffle to determine MDL in the way they describe. The precision proifie will give misleading estimates of the CV when the curve fit is poor, or where the zero standards are excluded from the curve fit and extrapolated CVs are presented in the proffle. These pitfalls are well-recognized hazards in curve-fitting data from immunometric assays, particularly at low concentrations.
A reliable method of calculating the MDL has been presented by Rodbard (2), although this does not appear to be widely implemented in data-processing software. A simple but nonetheless valid approach has been proposed by There are, as Rodbard (2) has pointed out, many definitions of sensitivity in the literature that are conceptually and statistically unsound. The "22% CV" rule, as presented by McConway et al. (1) , adds yet another. It would be unfortunate if immunoassayists were to be distracted by its apparent simplicity from using established and more-reliable methods of estimating the MDL.
